ArticleAnnals of medicine2026
Lipid-lowering medication reduces more target lesion than non-target lesion revascularizations: a cohort study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFactors related to the very long-term progression of atherosclerosis after stent implantation remain unclear.
aimsTo define factors predicting disease progression as either target lesion (TL) or a new site target lesion (NTL) coronary stenosis.
methodsIn a tertiary hospital, between June 2006 and March 2008, a prospective cohort registry of consecutive patients assigned to a coronary angiogram (
resultsDuring a median of 9.5 years follow-up, 639 (32.4%) patients had a cardiovascular event, including 253 (12.8%) cardiovascular deaths. Repeat percutaneous coronary interventions were more frequent in CCS than in ACS patients (144 (22.7%) vs. 204 (15.3%),
conclusionsStatin medication provided better protection from TL compared to NTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.